Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17735438 | 1.00 | KDM1A (0.52) | KDM1AMAOBGAAEPHX2MAOA | |
| SCHEMBL14771803 | 1.00 | KDM1A (0.52) | KDM1AMAOBGAAEPHX2MAOA | |
| SCHEMBL14771818 | 1.00 | KDM1A (0.52) | KDM1AMAOBGAAEPHX2MAOA | |
| SCHEMBL16253594 | 1.00 | KDM1A (0.52) | KDM1AMAOBGAAEPHX2MAOA | |
| SCHEMBL14771817 | 1.00 | KDM1A (0.52) | KDM1AMAOBGAAEPHX2MAOA | |
| SCHEMBL16253593 | 1.00 | KDM1A (0.52) | KDM1AMAOBGAAEPHX2MAOA | |
| SCHEMBL4567295 | 1.00 | KDM1A (0.52) | KDM1AMAOBGAAEPHX2MAOA | |
| SCHEMBL14771724 | 1.00 | KDM1A (0.52) | KDM1AMAOBGAAEPHX2MAOA | |
| SCHEMBL16253592 | 1.00 | KDM1A (0.52) | KDM1AMAOBGAAEPHX2MAOA | |
| SCHEMBL14771793 | 1.00 | KDM1A (0.52) | KDM1AMAOBGAAEPHX2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737458-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2024150250-A1 | A PROCESS FOR THE PREPARATION OF ATOGEPANT AND ITS INTERMEDIATES | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024134683-A1 | Novel process for the preparation of intermediate compounds used in the treatment of migraine | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2024-06-27 | — | — | WO | disclosed |
| US-20180127417-A1 | INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9850246-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850246-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9833448-B2 | Piperidinone carboxamide azaindane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170027925-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-02 | — | — | US | disclosed |
| US-9487523-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487523-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160130273-A1 | Process for Making CGRP Receptor Antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160130273-A1 | Process for Making CGRP Receptor Antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-05-12 | — | — | US | disclosed |
| US-9174989-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174989-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | disclosed |
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | disclosed |
| WO-2013138418-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027925-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, GPR65 | KDM1A 1612/4885MAOB 946/4885GAA 2581/4885 |
| US-20180127417-A1 | INTERMEDIATES FOR PREPARING CGRP RECEPTOR ANTAGONISTS | CALCR, CALCRL, VIPR1 | KDM1A 1616/4885MAOB 856/4885GAA 4256/4885 |
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | CCKBR, BDKRB2, CALCR | KDM1A 2137/4885MAOB 185/4885GAA 4109/4885 |
| US-20160130273-A1 | Process for Making CGRP Receptor Antagonists | CALCR, CALCRL, VIPR1 | KDM1A 1293/4885MAOB 857/4885GAA 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.